Literature DB >> 19644452

Expression and regulation of soluble epoxide hydrolase in adipose tissue.

Bart M De Taeye1, Christophe Morisseau, Julie Coyle, Joseph W Covington, Ayala Luria, Jun Yang, Sheila B Murphy, David B Friedman, Bruce B Hammock, Douglas E Vaughan.   

Abstract

Obesity is an increasingly important public health issue reaching epidemic proportions. Visceral obesity has been defined as an important element of the metabolic syndrome and expansion of the visceral fat mass has been shown to contribute to the development of insulin resistance and cardiovascular disease. To identify novel contributors to cardiovascular and metabolic abnormalities in obesity, we analyzed the adipose proteome and identified soluble epoxide hydrolase (sEH) in the epididymal fat pad from C57BL/6J mice that received either a regular diet or a "western diet." sEH was synthesized in adipocytes and expression levels increased upon differentiation of 3T3-L1 preadipocytes. Although normalized sEH mRNA and protein levels did not differ in the fat pads from mice receiving a regular or a "western diet," total adipose sEH activity was higher in the obese mice, even after normalization for body weight. Furthermore, peroxisome proliferator-activated receptor gamma (PPARgamma) agonists increased the expression of sEH in mature 3T3-L1 adipocytes in vitro and in adipose tissue in vivo. Considering the established role for sEH in inflammation, cardiovascular diseases, and lipid metabolism, and the suggested involvement of sEH in the development of type 2 diabetes, our study has identified adipose sEH as a potential novel therapeutic target that might affect the development of metabolic and cardiovascular abnormalities in obesity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19644452      PMCID: PMC2864128          DOI: 10.1038/oby.2009.227

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  55 in total

1.  An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension.

Authors:  John D Imig; Xueying Zhao; Constantine Z Zaharis; Jeffrey J Olearczyk; David M Pollock; John W Newman; In-Hae Kim; Takaho Watanabe; Bruce D Hammock
Journal:  Hypertension       Date:  2005-09-12       Impact factor: 10.190

2.  Diabetes and obesity: the twin epidemics.

Authors:  Simon Smyth; Andrew Heron
Journal:  Nat Med       Date:  2006-01       Impact factor: 53.440

3.  Differentiation-dependent regulation of the cyclooxygenase cascade during adipogenesis suggests a complex role for prostaglandins.

Authors:  Y Xie; X Kang; W E Ackerman; M A Belury; C Koster; B H Rovin; M B Landon; D A Kniss
Journal:  Diabetes Obes Metab       Date:  2006-01       Impact factor: 6.577

4.  Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.

Authors:  K Node; Y Huo; X Ruan; B Yang; M Spiecker; K Ley; D C Zeldin; J K Liao
Journal:  Science       Date:  1999-08-20       Impact factor: 47.728

5.  Soluble epoxide hydrolase is a therapeutic target for acute inflammation.

Authors:  Kara R Schmelzer; Lukas Kubala; John W Newman; In-Hae Kim; Jason P Eiserich; Bruce D Hammock
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-30       Impact factor: 11.205

6.  Eicosanoid imbalance in the NOD mouse is related to a dysregulation in soluble epoxide hydrolase and 15-PGDH expression.

Authors:  Michelle Rodriguez; Michael Clare-Salzler
Journal:  Ann N Y Acad Sci       Date:  2006-10       Impact factor: 5.691

Review 7.  Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism.

Authors:  Paul Poirier; Thomas D Giles; George A Bray; Yuling Hong; Judith S Stern; F Xavier Pi-Sunyer; Robert H Eckel
Journal:  Circulation       Date:  2005-12-27       Impact factor: 29.690

8.  The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase.

Authors:  Yi Liu; Yingjia Zhang; Kara Schmelzer; Tzong-Shyuan Lee; Xiang Fang; Yi Zhu; Arthur A Spector; Sarjeet Gill; Christophe Morisseau; Bruce D Hammock; John Y-J Shyy
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-02       Impact factor: 11.205

Review 9.  Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system.

Authors:  Brandon T Larsen; William B Campbell; David D Gutterman
Journal:  Trends Pharmacol Sci       Date:  2006-12-05       Impact factor: 14.819

10.  Regulation of adipocyte gene expression by polyunsaturated fatty acids.

Authors:  A V Hertzel; D A Bernlohr
Journal:  Mol Cell Biochem       Date:  1998-11       Impact factor: 3.396

View more
  53 in total

1.  Thyroid receptor antagonism as a contributory mechanism for adipogenesis induced by environmental mixtures in 3T3-L1 cells.

Authors:  Christopher D Kassotis; Erin M Kollitz; Kate Hoffman; Julie Ann Sosa; Heather M Stapleton
Journal:  Sci Total Environ       Date:  2019-02-18       Impact factor: 7.963

2.  Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice.

Authors:  Clothilde Roche; Marie Besnier; Roméo Cassel; Najah Harouki; David Coquerel; Dominique Guerrot; Lionel Nicol; Emmanuelle Loizon; Isabelle Remy-Jouet; Christophe Morisseau; Paul Mulder; Antoine Ouvrard-Pascaud; Anne-Marie Madec; Vincent Richard; Jeremy Bellien
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-27       Impact factor: 4.733

Review 3.  The Role of Cytochrome P450 Epoxygenases, Soluble Epoxide Hydrolase, and Epoxyeicosatrienoic Acids in Metabolic Diseases.

Authors:  Xizhen Xu; Rui Li; Guangzhi Chen; Samantha L Hoopes; Darryl C Zeldin; Dao Wen Wang
Journal:  Adv Nutr       Date:  2016-11-15       Impact factor: 8.701

Review 4.  Inflammatory lipid mediators in adipocyte function and obesity.

Authors:  Abishek Iyer; David P Fairlie; Johannes B Prins; Bruce D Hammock; Lindsay Brown
Journal:  Nat Rev Endocrinol       Date:  2010-02       Impact factor: 43.330

Review 5.  Eicosanoids in metabolic syndrome.

Authors:  James P Hardwick; Katie Eckman; Yoon Kwang Lee; Mohamed A Abdelmegeed; Andrew Esterle; William M Chilian; John Y Chiang; Byoung-Joon Song
Journal:  Adv Pharmacol       Date:  2013

Review 6.  Humble beginnings with big goals: Small molecule soluble epoxide hydrolase inhibitors for treating CNS disorders.

Authors:  Sydney Zarriello; Julian P Tuazon; Sydney Corey; Samantha Schimmel; Mira Rajani; Anna Gorsky; Diego Incontri; Bruce D Hammock; Cesar V Borlongan
Journal:  Prog Neurobiol       Date:  2018-11-14       Impact factor: 11.685

Review 7.  The 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic pain.

Authors:  Sean D Kodani; Bruce D Hammock
Journal:  Drug Metab Dispos       Date:  2015-03-11       Impact factor: 3.922

8.  Endoplasmic reticulum stress in the peripheral nervous system is a significant driver of neuropathic pain.

Authors:  Bora Inceoglu; Ahmed Bettaieb; Carlos A Trindade da Silva; Kin Sing Stephen Lee; Fawaz G Haj; Bruce D Hammock
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-06       Impact factor: 11.205

Review 9.  Soluble epoxide hydrolase in atherosclerosis.

Authors:  Yi-Xin Jim Wang; Arzu Ulu; Le-Ning Zhang; Bruce Hammock
Journal:  Curr Atheroscler Rep       Date:  2010-05       Impact factor: 5.113

Review 10.  Epoxyeicosatrienoic acids and glucose homeostasis in mice and men.

Authors:  James M Luther; Nancy J Brown
Journal:  Prostaglandins Other Lipid Mediat       Date:  2016-07-19       Impact factor: 3.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.